| [1] Drossman D A. Introduction. The Rome foundation and Rome III[J]. Neurogastroenterol Motil, 2007,19(10):783-786.[2] Ian M C, Tamar R K, Temitope O K, et al. Molecular analys is of the luminal and mucosal associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome[J]. Am J Physiol Gastrointest Liver Physiol, 2011,301(5):G799-G807.[3] Magdy E S. Irritable bowel syndrome: diagnosis and pathogenesis[J]. World J Gastroenterol, 2012,18(37):5151-5163.[4] Per G F, Ami D S, Magnus S. Irritable bowel syndrome[J]. Gastroenterol Res Pract, 2012,2012:612479.[5] Hungin A P, Whorwell P J, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: a international survey of 40,000 subjects[J]. Aliment Pharmacol Ther, 2003,17(5):643-650.[6] Schnrich S, Brockow T, Franke T, et al. Analyzing the content of outcome measures in clinical trails on irritable bowel syndrome using international classification of functioning disability and health as a reference[J]. Rehabilitation(Stuttg), 2006,45(3):172-180.[7] Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome[J]. Nutr Clin Pract, 2008,23(3):284-292.[8] 张声生,周涛,汪红兵.肠易激综合征中医药诊疗现状与挑战[J].世界华人消化杂志,2010,18(21):2216-2220.[9] Zhang S S. Thinking and strategy on the diagnosis and treatment of functional gastrointestinal disorders with integrative medicine[J]. Chin J Integr Med, 2009,15(2):83-85.[10] 张声生, 许文君, 汪正芳. 抑肝扶脾法治疗腹泻型肠易激综合征53例疗效观察[C].中华中医药学会脾胃病分会第二十三次全国脾胃病学术交流会论文汇编,2012:373-377.[11] 张涛, 潘峰, 徐建军. 痛泻要方干预脾虚肝郁型大鼠肠易激综合征的实验研究[J].中成药,2011,33(4):687-689.[12] 谭远忠,熊丽萍.痛泻要方加减联合西药治疗腹泻型肠易激综合征临床观察[J].中国中西医结合消化杂志,2012,20(9):415-416.[13] 张声生,汪正芳,郭乾坤,等.疏肝健脾方对腹泻型肠易激综合征大鼠5-羟色胺相关的结肠黏膜上皮分泌功能的影响[J].中华中医药杂志,2012,32(11):1516-1520.[14] Toshimi C, Kazunari Y, Shoko S, et al. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome[J]. Clin Exp Gastroenterol, 2013,25(6):123-128.[15] Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation,and abdominal pain in irritable bowel syndrome[J]. Am J Gastroenterol, 2011,106(7):1290-1298.[16] Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer[J]. Neurogastroenterol Motil, 2008,20(5):557-565.[17] Frber L, Haus U, Spth M, et al. Physiology and pathophysiology of the 5-HT3 receptor[J]. Scand J Rheumatol Suppl, 2004,119:2-8.[18] Wendy Atkinson, Lesley A. Houghton, Peter J. Whorwell, et al. Gender differences in plasma 5-hydroxytryptamine(5-HT) concentration in diarrhoea predominant irritable bowel syndrome(D-IBS): influence of the menstrual cycle[J]. Gastroenterology, 2003,124(4):338.[19] Hirata T, Funatsu T, Keto Y, et al. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS[J]. Inflammopharmacology, 2007,15(1):5-9.[20] Mayer E A, Berman S, Derbyshire S W, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients[J]. Aliment Pharmacol Ther, 2002,16(7):1357-1366.[21] El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome[J]. Scand J Gastroenterol, 2010,45(12):1435-1439.[22] Lineke M T, Anthony J C, Johan O, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders[J]. Biol Psychol, 2011,87(2):183-194.[23] Videlock J E, Adeyemo M, Licudine A, et al. Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome[J]. Gastroenterology, 2009,137(6):1954-1962. |
